Publications by authors named "Carl E Ruby"

Claim this Profile
C
Characterization of a Potential Therapeutic Anti-Canine PD-1 Single Domain Antibody Produced in Yeast.
Kartikeya Vijayasimha, Andrew J Annalora, Dan V Mourich, Carl E Ruby, Brian P Dolan

Vet Sci· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Promises and Perils of Human Biological Treatments for Immunotherapy in Veterinary Oncology.
Jeilene N Hambly, Carl E Ruby, Dan V Mourich, Shay Bracha, Brian P Dolan

Vet Sci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Creating a Selective Nanobody Against 3-Nitrotyrosine Containing Proteins.
Elise M Van Fossen, Sonia Grutzius, Carl E Ruby, Dan V Mourich, Chris Cebra

Front Chem· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exosomal proteomic signatures correlate with drug resistance and carboplatin treatment outcome in a spontaneous model of canine osteosarcoma.
Marcus A Weinman, Stephen A Ramsey, Haley J Leeper, Jacqueline V Brady, Andrew Schlueter, Carl E Ruby

Cancer Cell Int· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fasting reduces the incidence of vincristine-associated adverse events in dogs.
Margaret E Duckett, Kaitlin M Curran, Haley J Leeper, Carl E Ruby, Shay Bracha

Vet Comp Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Preliminary Proteomic Investigation of Circulating Exosomes and Discovery of Biomarkers Associated with the Progression of Osteosarcoma in a Clinical Model of Spontaneous Disease.
Jacqueline V Brady, Ryan M Troyer, Stephen A Ramsey, Haley Leeper, Liping Yang, Carl E Ruby

Transl Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exosomes from Osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells.
Ryan M Troyer, Carl E Ruby, Cheri P Goodall, Liping Yang, Claudia S Maier

Exp Cell Res· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic virus therapy for cancer.
Joe Goldufsky, Shanthi Sivendran, Sara Harcharik, Michael Pan, Sebastian Bernardo, Carl E Ruby

Oncolytic Virother· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.
Sanja B Turturro, Matthew S Najor, Carl E Ruby, Melody A Cobleigh, Abde M Abukhdeir

Breast Cancer Res Treat· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade.
Frederick J Kohlhapp, Joseph R Broucek, Tasha Hughes, Erica J Huelsmann, Jevgenijs Lusciks, Carl E Ruby

J Immunother Cancer· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines.
Joe Goldufsky, Stephen Wood, Behnam Hajihossainlou, Tooba Rehman, Omar Majdobeh, Carl E Ruby

J Med Microbiol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early-onset age-related changes in dendritic cell subsets can impair antigen-specific T helper 1 (Th1) CD4 T cell priming.
Michelle Farazi, Zachary Cohn, Justine Nguyen, Andrew D Weinberg, Carl E Ruby

J Leukoc Biol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging.
Michelle Farazi, Justine Nguyen, Josef Goldufsky, Stephanie Linnane, Lisa Lukaesko, Carl E Ruby

Cancer Immunol Immunother· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.
Howard L Kaufman, Carl E Ruby, Tasha Hughes, Craig L Slingluff

J Immunother Cancer· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival.
Nicole A Vasilevsky, Carl E Ruby, Peter J Hurlin, Andrew D Weinberg

Eur J Immunol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Signaling through OX40 enhances antitumor immunity.
Shawn M Jensen, Levi D Maston, Michael J Gough, Carl E Ruby, William L Redmond

Semin Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of aging on OX40 agonist-mediated cancer immunotherapy.
Carl E Ruby, Andrew D Weinberg

Cancer Immunol Immunother· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right.
Carl E Ruby, Melissa A Yates, Daniel Hirschhorn-Cymerman, Peter Chlebeck, Jedd D Wolchok

J Immunol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of OX40-mediated co-stimulation in T-cell activation and survival.
William L Redmond, Carl E Ruby, Andrew D Weinberg

Crit Rev Immunol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OX40-enhanced tumor rejection and effector T cell differentiation decreases with age.
Carl E Ruby, Andrew D Weinberg

J Immunol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.
Michael J Gough, Carl E Ruby, William L Redmond, Birat Dhungel, Alexis Brown

Cancer Res· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-12 is required for anti-OX40-mediated CD4 T cell survival.
Carl E Ruby, Ryan Montler, Rongxui Zheng, Suyu Shu, Andrew D Weinberg

J Immunol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 Nef assembles a Src family kinase-ZAP-70/Syk-PI3K cascade to downregulate cell-surface MHC-I.
Chien-Hui Hung, Laurel Thomas, Carl E Ruby, Katelyn M Atkins, Nicholas P Morris

Cell Host Microbe· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
Carl E Ruby, William L Redmond, Daniel Haley, Andrew D Weinberg

Eur J Immunol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2,3,7,8 Tetrachlorodibenzo-p-Dioxin (TCDD) Directly Enhances the Maturation and Apoptosis of Dendritic Cells In Vitro.
Carl E Ruby, Castle J Funatake, Nancy I Kerkvliet

J Immunotoxicol· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis